3D rendering of antibody drug conjugate molecules. Credit: Alpha Tauri 3D Graphics / Shutterstock.com.

Biocytogen Pharmaceuticals (Beijing) and Myricx Bio have signed an antibody evaluation, option and licence agreement for the development of antibody-drug conjugates (ADCs).

Myricx will provide its linker and payload and Biocytogen will conjugate them with its RenMice-derived fully human antibodies to create ADCs.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Biocytogen will conduct feasibility testing for these ADCs as part of its CRO [contract research organisation] services. If the option is exercised, Myricx will become responsible for advancing their development and commercialisation.

Biocytogen will be eligible to receive an upfront payment and may also be entitled to milestone payments related to ongoing development and commercialisation, in addition to single-digit royalties based on net sales.

The company’s antibodies have undergone screening for specificity, cross-species reactivity, high affinity, developability and internalisation activity specifically for ADC applications.

NMT is an enzyme that attaches a specific lipid modification to proteins which are crucial for the survival of cancer cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Myricx is creating a series of ADCs to tackle significant unmet requirements in cancer treatment.

These ADCs are built upon Myricx’s NMT inhibitor payload chemistry platform, demonstrating preclinical efficacy and safety across solid tumour-related antigens and types of cancer cells.

Biocytogen president and CEO Dr Yuelei Shen stated: “Myricx is a leading expert in NMTi payloads and we believe that the combination of both companies’ strengths will result in ADC drugs with first-in-class and best-in-class potential.”